Different mechanisms contribute to the biphasic pattern of carboxypeptidase U (TAFIa) generation during in vitro clot lysis in human plasma
- PMID: 12574805
Different mechanisms contribute to the biphasic pattern of carboxypeptidase U (TAFIa) generation during in vitro clot lysis in human plasma
Abstract
Carboxypeptidase U (CPU,TAFIa) recently gained interest as a significant player in dampening the fibrinolytic rate. The aim of this study was to investigate the time course of the generation of CPU activity during coagulation and fibrinolysis using an in vitro clot lysis model in human plasma. A first peak of CPU activity appeared after initiation of the coagulation phase and a second rise in CPU activity was observed during the fibrinolysis. The decrease in the proCPU plasma concentration followed the same trend as the appearance of the CPU activity. The direct thrombin inhibitor inogatran eliminated the CPU generation during coagulation but not during fibrinolysis. Addition of the plasmin inhibitor aprotinin during fibrinolysis resulted in a decrease in CPU activation during the lysis phase. These results demonstrate that proCPU was activated during coagulation by thrombin and during fibrinolysis by plasmin. Addition of a CPU inhibitor before initiation of clotting decreased the clot lysis time as expected. However, addition in the time period between the two peaks of CPU activity had no apparent effect on the clot lysis time.
Similar articles
-
Carboxypeptidase U (CPU, TAFIa, CPB2) in Thromboembolic Disease: What Do We Know Three Decades after Its Discovery?Int J Mol Sci. 2021 Jan 17;22(2):883. doi: 10.3390/ijms22020883. Int J Mol Sci. 2021. PMID: 33477318 Free PMC article. Review.
-
Plasma carboxypeptidase U (CPU, CPB2, TAFIa) generation during in vitro clot lysis and its interplay between coagulation and fibrinolysis.Thromb Haemost. 2017 Jul 26;117(8):1498-1508. doi: 10.1160/TH17-02-0097. Epub 2017 Jul 6. Thromb Haemost. 2017. PMID: 28692110
-
Carboxypeptidase U (CPU, carboxypeptidase B2, activated thrombin-activatable fibrinolysis inhibitor) inhibition stimulates the fibrinolytic rate in different in vitro models.J Thromb Haemost. 2018 Oct;16(10):2057-2069. doi: 10.1111/jth.14249. Epub 2018 Aug 30. J Thromb Haemost. 2018. PMID: 30053349
-
Inhibition of the procarboxypeptidase U (proCPU, TAFI, proCPB2) system due to hemolysis.J Thromb Haemost. 2019 Jun;17(6):878-884. doi: 10.1111/jth.14432. Epub 2019 May 2. J Thromb Haemost. 2019. PMID: 30887647
-
An update on the role of carboxypeptidase U (TAFIa) in fibrinolysis.Front Biosci (Landmark Ed). 2011 Jun 1;16(7):2427-50. doi: 10.2741/3864. Front Biosci (Landmark Ed). 2011. PMID: 21622187 Review.
Cited by
-
Lp(a) is not associated with diabetes but affects fibrinolysis and clot structure ex vivo.Sci Rep. 2014 Jun 17;4:5318. doi: 10.1038/srep05318. Sci Rep. 2014. PMID: 24937703 Free PMC article.
-
Carboxypeptidase U (CPU, TAFIa, CPB2) in Thromboembolic Disease: What Do We Know Three Decades after Its Discovery?Int J Mol Sci. 2021 Jan 17;22(2):883. doi: 10.3390/ijms22020883. Int J Mol Sci. 2021. PMID: 33477318 Free PMC article. Review.
-
Assays to quantify fibrinolysis: strengths and limitations. Communication from the International Society on Thrombosis and Haemostasis Scientific and Standardization Committee on fibrinolysis.J Thromb Haemost. 2023 Apr;21(4):1043-1054. doi: 10.1016/j.jtha.2023.01.008. Epub 2023 Jan 14. J Thromb Haemost. 2023. PMID: 36759279 Free PMC article. Review.
-
Thrombin Activatable Fibrinolysis Inhibitor (TAFI): An Updated Narrative Review.Int J Mol Sci. 2021 Apr 1;22(7):3670. doi: 10.3390/ijms22073670. Int J Mol Sci. 2021. PMID: 33916027 Free PMC article. Review.
-
Activated platelet-based inhibition of fibrinolysis via thrombin-activatable fibrinolysis inhibitor activation system.Blood Adv. 2020 Nov 10;4(21):5501-5511. doi: 10.1182/bloodadvances.2020002923. Blood Adv. 2020. PMID: 33166409 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources